Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 28:10:41.
doi: 10.3389/fmicb.2019.00041. eCollection 2019.

Drug Repurposing for the Treatment of Bacterial and Fungal Infections

Andrea Miró-Canturri  1 , Rafael Ayerbe-Algaba  1 , Younes Smani  1
Affiliations
Review

Drug Repurposing for the Treatment of Bacterial and Fungal Infections

Andrea Miró-Canturri et al. Front Microbiol. .

Erratum in

Abstract

Multidrug-resistant (MDR) pathogens pose a well-recognized global health threat that demands effective solutions; the situation is deemed a global priority by the World Health Organization and the European Centre for Disease Prevention and Control. Therefore, the development of new antimicrobial therapeutic strategies requires immediate attention to avoid the ten million deaths predicted to occur by 2050 as a result of MDR bacteria. The repurposing of drugs as therapeutic alternatives for infections has recently gained renewed interest. As drugs approved by the United States Food and Drug Administration, information about their pharmacological characteristics in preclinical and clinical trials is available. Therefore, the time and economic costs required to evaluate these drugs for other therapeutic applications, such as the treatment of bacterial and fungal infections, are mitigated. The goal of this review is to provide an overview of the scientific evidence on potential non-antimicrobial drugs targeting bacteria and fungi. In particular, we aim to: (i) list the approved drugs identified in drug screens as potential alternative treatments for infections caused by MDR pathogens; (ii) review their mechanisms of action against bacteria and fungi; and (iii) summarize the outcome of preclinical and clinical trials investigating approved drugs that target these pathogens.

Keywords: antimicrobial resistance; bacteria; fungi; infection; repurposing drug.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Antibacterial and antifungal mechanisms of action of repurposed drugs.
See this image and copyright information in PMC

References

    1. Aguinagalde L., Díez-Martínez R., Yuste J., Royo I., Gil C., Lasa Í, et al. (2015). Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections. J. Antimicrob. Chemother. 70 2608–2617. 10.1093/jac/dkv163 - DOI - PubMed
    1. Andersson J. A., Fitts E. C., Kirtley M. L., Ponnusamy D., Peniche A. G., Dann S. M., et al. (2016). New role for FDA-approved drugs in combating antibiotic-resistant bacteria. Antimicrob. Agents Chemother. 60 3717–3729. 10.1128/AAC.00326-16 - DOI - PMC - PubMed
    1. Andersson J. A., Sha J., Kirtley M. L., Reyes E., Fitts E. C., Dann S. M., et al. (2017). Combating multidrug-resistant pathogens with host-directed nonantibiotic therapeutics. Antimicrob. Agents Chemother. 62 e1943–e1917. 10.1128/AAC.01943-17 - DOI - PMC - PubMed
    1. Antoniani D., Rossi E., Rinaldo S., Bocci P., Lolicato M., Paiardini A., et al. (2013). The immunosuppressive drug azathioprine inhibits biosynthesis of the bacterial signal molecule cyclic-di-GMP by interfering with intracellular nucleotide pool availability. Appl. Microbiol. Biotechnol. 97 7325–7336. 10.1007/s00253-013-4875-0 - DOI - PubMed
    1. Antunes L. C. S., Imperi F., Minandri F., Visca P. (2012). In vitro and in vivo antimicrobial activities of gallium nitrate against multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 56 5961–5970. 10.1128/AAC.01519-12 - DOI - PMC - PubMed